Researcher
Jo Van Ginderachter
- Keywords (Vrije Universiteit Brussel):Applied biological sciences, biotechnology
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Adaptive immunology, Bacteriology
- Disciplines (Vrije Universiteit Brussel):Applied immunology
Affiliations
- Cellular and Molecular Immunology (Research group)
Responsible
From1 Oct 1995 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Jan 2024 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2019 → 31 Dec 2023 - Department of Bio-engineering Sciences (Department)
Member
From8 Apr 2019 → 30 Sep 2019 - Van Ginderachter Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2012 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2010 → 20 Oct 2022 - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 1999 → 30 Sep 2014
Projects
1 - 10 of 26
- Therapeutic targeting of tumor-associated macrophages with anti-CD163 Nanobody-drug conjugates as novel cancer therapyFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Blocking the immunoregulatory family members D-dopachrome tautomerase (D-DT) and Macrophage Migration Inhibitory Factor (MIF) to improve immunotherapy of cancerFrom1 Nov 2022 → TodayFunding: FWO fellowships
- SRP-Onderzoekszwaartepunt: ITAREG: Molecular Imaging and TArgeting of immunoREGulatory cells in Inflammatory diseases and cancerFrom1 Nov 2022 → TodayFunding: BOF - projects
- IOF Accelerator:Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)From1 Oct 2022 → 31 Mar 2024Funding: IOF - technology validation in real environment
- SBO Project : LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
- Optimized anti-Neuropilin-1 Nanobody formats as cancer therapyFrom1 Nov 2021 → TodayFunding: FWO fellowships
- Immunological memory of the macrophage niche (MacNicheMemo).From1 Jan 2021 → TodayFunding: BOF - iBOF
- Blocking Lipocalin-2 (Lcn-2) using Nanobodies as novel cancer therapyFrom1 Nov 2020 → TodayFunding: FWO fellowships
- Seahorse platform: the Agilent Seahorse Flux Analyser with integrated normalization systemFrom1 May 2020 → TodayFunding: Hercules - Small and Medium size research infrastructure
Publications
41 - 50 of 101
- Interactions among myeloid regulatory cells in cancer(2019)
Authors: Viktor Umansky, Gosse J Adema, Jaroslaw Baran, Sven Brandau, Jo A Van Ginderachter, Xiaoying Hu, Jadwiga Jablonska, Slavko Mojsilovic, Helen A Papadaki, Yago Pico de Coaña, et al.
Pages: 645-660 - How to measure the immunosuppressive activity of MDSC(2019)
Authors: Annika M Bruger, Anca Dorhoi, Gunes Esendagli, Katarzyna Barczyk-Kahlert, Pierre Van Der Bruggen, Marie Lipoldova, Tomas Perecko, Juan F Santibanez, Margarida Saraiva, Jo A Van Ginderachter, et al.
Pages: 631-644 - Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy(2019)
Authors: Aurelie Hanoteau, Jared M Newton, Rosemarie Krupar, Chen Huang, Hsuan-Chen Liu, Angelina Gaspero, Robyn D Gartrell, Yvonne M Saenger, Thomas D Hart, Saskia J Santegoets, et al.
- Nanobody-mediated targeting of tumor-associated macrophages for cancer therapy(2019)
Authors: Evangelia Bolli, Jo A Van Ginderachter
- Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies(2018)
Authors: Sabrina Rizzolio, Gabriella Cagnoni, Chiara Battistini, Stefano Bonelli, Claudio Isella, Jo A Van Ginderachter, René Bernards, Federica Di Nicolantonio, Silvia Giordano, Luca Tamagnone
Pages: 3976-3990 - The Transcription Factor ZEB2 Is Required to Maintain the Tissue-Specific Identities of Macrophages(2018)
Authors: Charlotte L Scott, Wouter T'Jonck, Liesbet Martens, Helena Todorov, Dorine Sichien, Bieke Soen, Johnny Bonnardel, Sofie De Prijck, Niels Vandamme, Robrecht Cannoodt, et al.
Pages: 312-325.e5 - The role of hepatic macrophages in liver metastasis(2018)
Authors: Jiri Keirsse, Helena Van Damme, Xenia Geeraerts, Alain Beschin, Geert Raes, Jo A Van Ginderachter
Pages: 202-215 - Neutrophils enhance early Trypanosoma brucei infection onset(2018)
Authors: Guy Caljon, Dorien Mabille, Carl De Trez, Massimiliano Mazzone, Fabienne Tacchini-Cottier, Marie Malissen, Jo A Van Ginderachter, Stefan Magez, Patrick De Baetselier, Jan Van Den Abbeele, et al.
- Targeting Protumoral Tumor-Associated Macrophages with Nanobody-Functionalized Nanogels through Strain Promoted Azide Alkyne Cycloaddition Ligation(2018)
Authors: Lutz Nuhn, Evangelia Bolli, Sam Massa, Isabel Vandenberghe, Kiavash Movahedi, Bart Devreese, Jo A Van Ginderachter, Bruno G De Geest
Pages: 2394–2405 - RoMo(2018)
Authors: Kiavash Movahedi, Robert Wiegmann, Karen De Vlaminck, Jo A Van Ginderachter, Viacheslav O Nikolaev
Pages: 1778-1792
Patents
1 - 6 of 6
- Tumor-associated dendritic cell preparations and uses thereof (Inventor)
- Non-blocking human ccr8 binders (Inventor)
- Human ccr8 binders (Inventor)
- Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages (Inventor)
- A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer (Inventor)
- Murine cross-reactive human ccr8 binders (Inventor)